Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4414-4421

  Silva, Jean Jerley N ^a   Pavanelli, Wander R ^a   Pereira, José Clayston M ^a   Silva, João S ^a   Franco, Douglas W ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

[RUTHENIUM (NITRIC OXIDE) (AMMONIA) 4 IMIDAZOLE] (BF4)3; [RUTHENIUM (NITRIC OXIDE) (AMMONIA) 4 ISONICOTINAMIDE] (BF4)3; [RUTHENIUM (NITRIC OXIDE) (AMMONIA) 4 PYRIDINE] (BF4)3; ANTITRYPANOSOMAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; EPIMASTIGOTE; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; MAXIMUM ALLOWABLE CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

ANIMALS; CHAGAS DISEASE; FEMALE; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; NITRIC OXIDE DONORS; RUTHENIUM COMPOUNDS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 70349320506     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00104-09     Document Type: Article

References (55)

1. Abrahamsohn, I. A., and R. L. Coffman. 1995. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J. Immun. 155:3955-3963.
2. Aliberti, J. C., F. S. Machado, J. T. Souto, A. P. Campanelli, M. M. Teixeira, R. T. Gazzinelli, and J. S. Silva. 1999. β-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect. Immun. 67:4819-4826.
3. Aufderheide, A. C., W. Salo, M. Madden, J. Streitz, J. Buikstra, F. Guhl, B. Arriaza, C. Renier, L. E. Wittmers, Jr., G. Fornaciari, and M. Allison. 2004. A 9000-year record of Chagas' disease. Proc. Natl. Acad. Sci. USA 101:2034-2039.
4. Bocedi, A., L. Gradoni, E. Menegatti, and P. Ascenzi. 2004. Kinetics of parasite cysteine proteinase inactivation by NO-donors. Biochem. Biophys. Res. Commun. 315:710-718.
5. Bonavida, B., S. Khineche, S. Huerta-Yepez, and H. Garbán. 2006. Therapeutic potential of nitric oxide in cancer. Drug Resist. Updat. 9:157-173.
6. Borges, S. S. S., C. U. Davanzo, E. E. Castellano, J. Z-Schpector, S. C. Silva, and D. W. Franco. 1998. Ruthenium nitrosyl complexes with N-heterocyclic ligands. Inorg. Chem. 37:2670-2677.
7. Brener, Z. 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 4:389-396.
8. Brener, Z. 1969. The behavior of slender and stout forms of Trypanosoma cruzi in the blood-stream of normal and immune mice. Ann. Trop. Med. Parasitol. 63:215-220.
9. Bruce, R. D. 1985. An up-and-down procedure for acute toxicity testing. Fundam. Appl. Toxicol. 5:151-157.
10. Cardillo, F., J. C. Voltarelli, S. G. Reed, and J. S. Silva. 1996. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect. Immun. 64:128-134.
11. Cerecetto, H., and M. González. 2002. Chemotherapy of Chagas' disease: status and new development. Curr. Top. Med. Chem. 2:1187-1213.
12. Clarke, M. J. 1978. Electrochemistry, synthesis, and spectra of pentaammineruthenium( III) complexes of cytidine, adenosine, and related ligands. J. Am. Chem. Soc. 100:5068-5075.
13. Colasanti, M., L. Gradoni, M. Mattu, T. Persichini, L. Salvati, G. Venturini, and P. Ascenzi. 2002. Molecular bases for the anti-parasitic effect of NO. Int. J. Mol. Med. 9:131-134.
14. Coura, J. R., and S. L. Castro. 2002. A critical review on Chagas' disease chemotherapy. Mem. Inst. Oswaldo Cruz 97:3-24.
15. Filho, J. R. O., W. C. Silva, J. C. M. Pereira, and D. W. Franco. 2006. Binding of cysteine and glutathione to Ru(II) and Ru(III) centers: formation and products reactivities. Inorg. Chim. Acta 359:2888-2895.
16. Gazzinelli, R. T., I. P. Oswald, S. Hieny, S. L. James, and A. Sher. 1992. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur. J. Immunol. 22:2501-2506.
17. Gelb, M. H., and W. G. J. Hol. 2002. Drugs to combat tropical protozoan parasites. Science 297:343-344.
18. Gutteridge, J. M., and B. Halliwell. 2000. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. N. Y. Acad. Sci. 899: 136-147.
19. Huang, H., J. Chan, M. Wittner, L. A. Jelicks, S. A. Morris, S. M. Factor, L. M. Weiss, V. L. Braunstein, C. J. Bacchi, N. Yarlett, M. Chandra, J. Shirani, and H. B. Tanowitz. 1999. Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice. J. Mol. Cell. Cardiol. 31:75-88.
20. Ishii, T., O. Sunami, H. Nakajima, H. Nishio, T. Takeuchi, and F. Hata. 1999. Critical role of sulfenic acid formation of thiols in the inactivation of flyceraldehyde-3-phosphate dehydrogenase by nitric oxide. Biochem. Pharmacol. 58:133-143.
21. -): modulation of the release of NO by the trans-effect. Inorg. Chim. Acta 358:2883-2890.
22. Machado, F. S., G. A. Martins, J. C. S. Aliberti, F. L. A. C. Mestriner, F. Q. Cunha, and J. S. Silva. 2000. Trypanosoma cruzi-infected cardiomuocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation 102:3003-3008.
23. Marks, G. S., B. E. McLaughlin, S. L. Jimmo, M. Poklewska-Koziell, J. F. Bien, and K. Nakatsu. 1995. Time-dependent increase in nitric oxide formation concurrent with vasodilation induced by sodium nitroprusside, 3-morpholinosydnonimine, and S-nitroso-N-acetylpenicillamine but not by glyceryl trinitrate. Drug Metab. Dispos. 23:1248-1252.
24. Martinez-Díaz, R. A., J. A. Escario, J. J. Nogal-Ruiz, and A. Gómez-Barrio. 2001. Biological characterization of Trypanosoma cruzi strains. Mem. Inst. Oswaldo Cruz 96:53-59.
25. Martins, G. A., A. G. Cardoso, J. C. S. Aliberti, and J. S. Silva. 1998. Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunol. Lett. 63:113-120.
26. Maya, J. D., B. K. Cassels, P. Iturriaga-Vásquez, J. Ferreira, M. Faúdez, N. Galanti, A. Ferreira, and A. Morello. 2007. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with mammalian host. Comp. Biochem. Physiol. A 146:601-620.
27. Napoli, C., and L. J. Ignarro. 2003. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. Toxicol. 43:97-123.
28. 2+. Polyhedron 26:4746-4750.
29. Perrin, D. D., W. L. F. Armarego, and D. R. Perrin. 1980. Purification of laboratory chemicals. Pergamon Press, Elmsford, NY.
30. Petray, P., E. Castaños-Velez, S. Grinstein, A. Orn, and M. E. Rottenberg. 1995. Role of nitric oxide in resistance and histopathology during experimental infection with Trypanosoma cruzi. Immunol. Lett. 47:121-126.
31. Reesink, H. W. 2004. European strategies against the parasite transfusion risk risque parasitaire, quelles stratégies en Europe? Transfus. Clin. Biol. 12:1-4.
32. Rodriguez, J. A., A. Souza-Torsoni, D. W. Franco, and M. Haun. 1997. Abstr. 24th Reun. Anual Soc. Bras. Bioquím. Biol. Mol. (SBBq), Caxambu, Brazil, 3 to 6 May 1997, abstr. S-32.
33. Roncaroli, F., and J. A. Olabe. 2005. The reactions of nitrosyl complexes with cysteine. Inorg. Chem. 44:4719-4727.
34. Saraiva, J., C. Vega, M. Rolon, R. Silva, M. L. A. Silva, P. M. Donate, J. K. Bastos, A. Gómez-Barrio, and S. Albuquerque. 2007. In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi. Parasitol. Res. 100:791-795.
35. Schlede, E., E. Genschow, H. Spielmann, G. Stropp, and D. Kayser. 2005. Oral acute toxic class: a successful alternative to the oral LD50 test. Regulat. Toxicol. Pharmacol. 42:15-23.
36. Schmunis, G. A. 1991. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 31:547-557.
37. Shriver, D. F. 1969. The manipulation of air-sensitive compounds. McGraw- Hill, New York, NY.
38. Silva, J. J. N., A. L. Osakabe, W. R. Pavanelli, J. S. Silva, and D. W. Franco. 2007. In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br. J. Pharmacol. 152:112-121.
39. Silva, J. S., F. S. Machada, and G. A. Martins. 2003. The role of nitric oxide in the pathogenesis of Chagas disease. Front. Biosci. 1:314-315.
40. Souza, D. H. F., R. C. Garratt, A. P. U. Araújo, B. G. Guimarães, W. D. P. Jesus, P. A. M. Michels, V. Hannaert, and G. Oliva. 1998. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. FEBS Lett. 424:131-135.
41. Stefaneli, E. V. 2008. M. D. Sobre a redução do óxido nítrico em complexos de tetraaminas de rutênio (II). University of São Paulo, São Carlos, Brazil.
42. Sun, J., L. J. Druhan, and J. L. Zweier. 2008. Dose dependent effects of reactive oxygen and nitrogen species on the function of neuronal nitric oxide synthase. Arch. Biochem. Biophys. 471:126-133.
43. Tfouni, E., M. Krieger, B. McGarvey, and D. W. Franco. 2003. Structure, chemical and photochemical reactivity and biological activity of some ruthenium nitrosyl complexes. Coord. Chem. Rev. 236:57-69.
44. Toledo, J. C., H. A. S. Silva, M. Scarpellini, V. Mori, A. J. Camargo, M. Bertoti, and D. W. Franco. 2004. Ruthenium tetraamine as a model of nitric oxide donor compounds. Eur. J. Inorg. Chem. 9:1879-1885.
45. 3, a new nitric oxide donor. Nitric Oxide 6:247-354.
46. Turrens, J. F. 2004. Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. Mol. Aspects Med. 25:211-220.
47. Valdez, C. A., J. E. Saavedra, B. M. Showalter, K. M. Davies, T. C. Wilde, M. L. Citro, J. J. Barchi, Jr., J. R. Deschamps, D. Parrish, S. El-Gayar, U. Schleicher, C. Bogdan, and L. K. Keefer. 2008. Hydrolytic reactivity trends among potential prodrugs of the O2-glycosylated diazeniumdiolate family. Targeting nitric oxide to macrophages for antileishmanial activity. J. Med. Chem. 51:3961-3970.
48. Venturini, G., L. Salavati, M. Muolo, M. Colasanti, L. Gradoni, and P. Ascenzi. 2000. Nitric oxide inhibits cruzipain, the major papain-like cysteine proteinase from Trypanosoma cruzi. Biochem. Biophys. Res. Commun. 270: 437-441. (Pubitemid 30446854)
49. Verlinde, C. L. M. J., M. Callens, S. Van Calenbergh, A. Van Aerschot, P. Herdewijn, V. Hannaert, P. A. M. Michels, F. R. Opperdoes, and W. G. J. Hol. 1994. Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. J. Med. Chem. 37:3605-3613.
50. Verlinde, C. L. M. J., V. Hannaert, C. Blonski, M. Willson, J. J. Périé, L. A. Fathergill-Gilmore, F. R. Opperdoes, M. H. Gelb, W. G. J. Hol, and P. A. M. Michels. 2001. Glycolysis as target for the design of new anti-trypanosome drugs. Drug Resist. Updat. 4:1-14.
51. Vespa, G. N. R., F. Q. Cunha, and J. S. Silva. 1994. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect. Immun. 62:5177-5182.
52. Vieira, P. C., J. Mafezoli, M. T. Pupo, J. B. Fernande, M. F. G. F. Silva, S. Albuquerque, G. Oliva, and F. Pavão. 2001. Strategies for the isolation and identification of trypanocidal compounds from the rutales. Pure Appl. Chem. 73:617-622.
53. Waghabi, M. C., M. Keramidas, J. J. Feige, T. C. Araujo-Jorge, and S. Bailly. 2005. Activation of transforming growth factor beta by Trypanosoma cruzi. Cell. Microbiol. 7:511-517.
54. Yun, M., C. G. Park, J. Y. Kim, and H. W. Park. 2000. Structural analysis of glyceraldehyde 3-phosphate dehydrogenase from Escherichia coli: direct evidence of substrate binding and cofactor-induced conformational changes. Biochemistry 39:10702-10710.
55. Zimmermann, M. 1983. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.